Over-inhibition: a model for developmental intellectual disability

Trends in Neurosciences

Volumn 30, Issue 10, 2007, Pages 497-503

  Fernandez, Fabian ^a   Garner, Craig C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; ARTICLE; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DEVELOPMENTAL INTELLECTUAL DISABILITY; DISEASE ASSOCIATION; DOWN SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; KINDLING; LEARNING; MEMORY; NERVE CELL PLASTICITY; NEUROFIBROMATOSIS; NEWBORN DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN MALNUTRITION; RETT SYNDROME;

BRAIN; CHILD; DEVELOPMENTAL DISABILITIES; ENVIRONMENT; HUMANS; INHIBITION (PSYCHOLOGY); MALNUTRITION; MODELS, BIOLOGICAL; NEUROFIBROMATOSIS 1; NEURONAL PLASTICITY;

EID: 34848891591     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2007.07.005     Document Type: Article

References (80)

1. Coyle J.T., et al. The neurobiological consequences of Down syndrome. Brain Res. Bull. 16 (1986) 773-787
2. Lacey D.J., and Terplan K. Abnormal cerebral cortical neurons in a child with maternal PKU syndrome. J. Child Neurol. 2 (1987) 201-204
3. Benitez-Bribiesca L., et al. Dendritic spine pathology in infants with severe protein-calorie malnutrition. Pediatrics 104 (1999) e21
4. Chechlacz M., and Gleeson J.G. Is mental retardation a defect of synapse structure and function?. Pediatr. Neurol. 29 (2003) 11-17
5. Turrigiano G.G., and Nelson S.B. Hebb and homeostasis in neuronal plasticity. Curr. Opin. Neurobiol. 10 (2000) 358-364
6. Hendry S.H., and Jones E.G. Reduction in number of immunostained GABAergic neurones in deprived-eye dominance columns of monkey area 17. Nature 320 (1986) 750-753
7. Seil F.J., et al. Morphological correlates of altered neuronal activity in organotypic cultures chronically exposed to anti-GABA agents. Brain Res. Dev. Brain Res. 77 (1994) 123-132
8. McKinney R.A., et al. Miniature synaptic events maintain dendritic spines via AMPA receptor activation. Nat. Neurosci. 2 (1999) 44-49
9. Ziv N.E., and Smith S.J. Evidence for a role of dendritic filopodia in synaptogenesis and spine formation. Neuron 17 (1996) 91-102
10. Watt A.J., et al. Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. Neuron 26 (2000) 659-670
11. Ehlers M.D. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat. Neurosci. 6 (2003) 231-242
12. A receptors. Ann. N. Y. Acad. Sci. 868 (1999) 654-666
13. Martynyuk A.E., et al. Impaired glutamatergic synaptic transmission in the PKU brain. Mol. Genet. Metab. 86 (2005) S34-S42
14. Kwon H., et al. Functional neuroanatomy of visuospatial working memory in fragile X syndrome: relation to behavioral and molecular measures. Am. J. Psychiatry 158 (2001) 1040-1051
15. Hyman S.L., et al. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65 (2005) 1037-1044
16. Li W., et al. The HMG-CoA reductase inhibitor Lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 15 (2005) 1961-1967
17. Costa R.M., et al. Mechanism for the learning deficits in a mouse model of neurofimbromatosis type 1. Nature 415 (2002) 526-530
18. Shilyansky C., et al. Impaired response planning and increased prefrontal cortex inhibition in a mouse model of neurofibromatosis type I. Abstr. Soc. Neurosci. (2006) 264.18
19. Luebke J., et al. Prenatal protein malnutrition results in increased frequency of miniature inhibitory synaptic currents in rat CA1 pyramidal cells. Synapse 37 (2000) 23-31
20. Chang Y.M., et al. Prenatal protein malnutrition results in increased frequency of miniature inhibitory postsynaptic currents in rat CA3 interneurons. Nutr. Neurosci. 6 (2003) 263-267
21. Morgane P.J., et al. Effects of prenatal protein malnutrition on the hippocampal formation. Neurosci. Biobehav. Rev. 26 (2002) 471-483
22. Stern W.C., et al. Developmental protein malnutrition in the rat: Effects on single-unit activity in the frontal cortex. Brain Res. 306 (1984) 227-234
23. Stern W.C., et al. Spontaneous forebrain neuronal activity in developmentally protein malnourished rats. Brain Res. 285 (1983) 95-98
24. Soto-Moyano R., et al. Prenatal protein malnutrition alters synaptic mechanisms of callosal connections in the rat visual cortex. Int. J. Dev. Neurosci. 16 (1998) 75-84
25. 2 mRNA levels. Neuroreport 14 (2003) 1731-1735
26. Palmer A.A., et al. Prenatal protein deprivation in rats induces changes in prepulse inhibition and NMDA receptor binding. Brain Res. 996 (2004) 193-201
27. Shultz P.L., et al. Prenatal protein malnutrition enhances stimulus control by CDP, but not a CDP/THIP combination in rats. Pharmacol. Biochem. Behav. 73 (2002) 759-767
28. Amir R.E., et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23 (1999) 185-188
29. Nan X., et al. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88 (1997) 471-481
30. Young J.I., et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17551-17558
31. Dani V.S., et al. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett Syndrome. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12560-12565
32. Asaka Y., et al. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol. Dis. 21 (2006) 217-227
33. Moretti P., et al. Learning and memory and synaptic plasticity are impaired in a mouse model of rett syndrome. J. Neurosci. 26 (2006) 319-327
34. Chang Q., et al. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49 (2006) 341-348
35. Tofil N.M., et al. Deep sedation with propofol in patients with Rett syndrome. J. Child Neurol. 21 (2006) 210-213
36. Lejeune J., et al. Le mongolisme, premier exemple d'aberration autosomique humain. Ann. Genet. 1 (1959) 92-101
37. Kurt M.A., et al. Synaptic deficit in the temporal cortex of partial trisomy 16 Ts65Dn mice. Brain Res. 858 (2000) 191-197
38. Belichenko P.V., et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 480 (2004) 281-298
39. Hanson J.E., et al. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down syndrome. J. Physiol. 579 (2007) 53-67
40. Kleschevnikov A.M., et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 24 (2004) 8153-8160
41. Siarey R.J., et al. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 38 (1999) 1917-1920
42. Seregaza Z., et al. Mouse models of cognitive disorders in Trisomy 21: A review. Behav. Genet. 36 (2006) 387-404
43. Bimonte-Nelson H.A., et al. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav. Brain Res. 139 (2003) 47-57
44. Bear M.F., et al. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27 (2004) 370-377
45. McBride S.M., et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45 (2005) 753-764
46. Yan Q.J., et al. Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49 (2005) 1053-1066
47. Fagiolini M., and Hensch T. Inhibitory threshold for critical-period activation in primary visual cortex. Nature 404 (2000) 183-186
48. A circuits for visual cortical plasticity. Science 303 (2004) 1681-1683
49. Hensch T.K., and Stryker M.P. Columnar architecture sculpted by GABA circuits in developing cat visual cortex. Science 303 (2004) 1678-1681
50. A-mediated inhibition. Science 284 (1999) 962-965
51. Zheng W., and Knudsen E.I. GABAergic inhibition antagonizes adaptive adjustment of the owl's auditory space map during the initial phase of plasticity. J. Neurosci. 21 (2001) 4356-4365
52. Wong M.L., and Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2 (2001) 343-351
53. Santarelli L., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
54. Meltzer L.A., et al. Hippocampal neurogenesis is required for lasting antidepressant effects of Fluoxetine. Abstr. Soc. Neurosci. (2006) 418.2
55. Goddard G.V. Development of epileptic seizures through brain stimulation at low intensity. Nature 214 (1967) 1020-1021
56. McNamara J.O., et al. The kindling model of epilepsy: A review. Prog. Neurobiol. 15 (1980) 139-159
57. Mason C.R., and Cooper R.M. A permanent change in convulsive threshold in normal and brain-damaged rats, with repeated small doses of pentylenetetrazol. Epilepsia 13 (1972) 663-674
58. Malenka R.C. The long-term potential of LTP. Nat. Rev. Neurosci. 4 (2003) 923-926
59. Stelzer A., et al. Activation of NMDA receptors blocks GABAergic inhibition in an in vitro model of epilepsy. Nature 326 (1987) 698-701
60. Corda M.G., et al. Decrease in GABAergic function induced by pentylenetetrazol kindling in rats: Antagonism by MK-801. J. Pharmacol. Exp. Ther. 262 (1992) 792-800
61. Morimoto K. Seizure-triggering mechanisms in the kindling model of epilepsy: Collapse of GABA-mediated inhibition and activation of NMDA receptors. Neurosci. Biobehav. Rev. 13 (1989) 253-260
62. Cain D.P., et al. Effects of protein synthesis inhibition on kindling in the mouse. Exp. Neurol. 68 (1980) 409-419
63. Landfield P.W., et al. Brain aging correlates: Retardation by hormonal-pharmacological treatments. Science 214 (1981) 581-584
64. Fernandez F., et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 10 (2007) 411-413
65. A receptor subtype selective cognition enhancers. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 233-239
66. Owens D.F., and Kriegstein A.R. Is there more to GABA than synaptic inhibition?. Nat. Rev. Neurosci. 3 (2002) 715-727
67. Tozuka Y., et al. GABAergic excitation promotes neuronal differentiation in adult hippocampal progenitor cells. Neuron 47 (2005) 803-815
68. Deisseroth K., et al. Excitation-neurogenesis coupling in adult neural stem/progenitor cells. Neuron 42 (2004) 535-552
69. Venkatesan A., et al. Adult hippocampal neurogenesis: Regulation by HIV and drugs of abuse. Cell. Mol. Life Sci. 64 (2007) 2120-2132
70. Marczynski T.J., et al. Chronic administration of flumazenil increases life span and protects rats from age-related loss of cognitive functions: A benzodiazepine/GABAergic hypothesis of brain aging. Neurobiol. Aging 15 (1994) 69-84
71. Corbett J.A., et al. Mental retardation and developmental disabilities. In: Wortis J. (Ed). Epilepsy (1975), Bruner/Mazel 70-111
72. Kulkantrakorn K., and Geller T.J. Seizures in neurofibromatosis 1. Pediatr. Neurol. 19 (1998) 347-350
73. Vivarelli R., et al. Epilepsy in neurofibromatosis 1. J. Child Neurol. 18 (2003) 338-342
74. Stafstrom C.E., et al. Seizures in children with Down syndrome: Etiology, characteristics and outcome. Dev. Med. Child Neurol. 33 (1991) 191-200
75. Stafstrom C.E., and Konkol R.J. Infantile spasms in children with Down syndrome. Dev. Med. Child Neurol. 36 (1994) 576-585
76. Prasher V.P. Epilepsy and associated effects on adaptive behaviour in adults with Down syndrome. Seizure 4 (1995) 53-56
77. McVicker R.W., et al. Prevalence and associated features of epilepsy in adults with Down's syndrome. Br. J. Psychiatry 164 (1994) 528-532
78. Puri B.K., et al. Age of seizure onset in adults with Down's syndrome. Int. J. Clin. Pract. 55 (2001) 442-444
79. Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev. 27 (2005) 246-252
80. Bronzino J.D., et al. Effects of prenatal protein malnutrition on perforant path kindling in the rat. Brain Res. 515 (1990) 45-50